Abstract OT3-02-11: Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Efficacy And Safety ◽

Eribulin Mesylate ◽

Phase 2 Study ◽

Abstract P6-14-05: Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

10.1158/1538-7445.sabcs17-p6-14-05 ◽

2018 ◽

Author(s):

J Smith ◽

A Irwin ◽

L Jensen ◽

K Tedesco ◽

S Misir ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Efficacy And Safety ◽

Eribulin Mesylate ◽

Phase 2 Study ◽

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.09.007 ◽

2020 ◽

Vol 20 (2) ◽

pp. 160-167

Author(s):

John Smith ◽

Amy Irwin ◽

Lori Jensen ◽

Karen Tedesco ◽

Soamnauth Misir ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population

Indian Journal of Cancer ◽

10.4103/0019-509x.146779 ◽

2014 ◽

Vol 51 (3) ◽

pp. 272 ◽

Cited By ~ 1

Author(s):

N Majid ◽

S Boutayeb ◽

H Errihani

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2018.04.001 ◽

2018 ◽

Vol 18 (6) ◽

pp. 433-440.e1 ◽

Cited By ~ 4

Author(s):

Karen A. Cadoo ◽

Peter A. Kaufman ◽

Andrew D. Seidman ◽

Cassandra Chang ◽

Dongyuan Xing ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Early Stage ◽

Growth Factor Receptor ◽

Phase 2 ◽

Eribulin Mesylate ◽

Phase 2 Study ◽

Epidermal Growth ◽

Dose Dense

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

JAMA Network Open ◽

10.1001/jamanetworkopen.2019.16211 ◽

2019 ◽

Vol 2 (11) ◽

pp. e1916211 ◽

Cited By ~ 3

Author(s):

Neil M. Iyengar ◽

Lillian M. Smyth ◽

Diana Lake ◽

Ayca Gucalp ◽

Jasmeet C. Singh ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Human Epidermal Growth Factor ◽

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

Annals of Translational Medicine ◽

10.21037/atm-21-4273 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Hui-Qiang Zhang ◽

Jin-Mei Zhou ◽

Shao-Hua Zhang ◽

Li Bian ◽

Jin-Yi Xiao ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Low Dose ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Hormone Receptor Positive ◽

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

International Journal of Cancer ◽

10.1002/ijc.31738 ◽

2018 ◽

Vol 144 (4) ◽

pp. 877-885 ◽

Cited By ~ 7

Author(s):

Hans Tesch ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Hormone Receptor Positive ◽

Phase Iiib ◽

A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06329-x ◽

2021 ◽

Author(s):

Sara M. Balch ◽

Ines Vaz-Luis ◽

Tianyu Li ◽

Nabihah Tayob ◽

Esha Jain ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

Epidermal Growth ◽

Potential Impact

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

The Breast Journal ◽

10.1111/tbj.13516 ◽

2020 ◽

Vol 26 (3) ◽

pp. 368-375

Author(s):

Karen A. Gelmon ◽

Massimo Cristofanilli ◽

Hope S. Rugo ◽

Angela M. DeMichele ◽

Anil A. Joy ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Hormone Receptor Positive ◽

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.025 ◽

2021 ◽

Vol 153 ◽

pp. 223-233

Author(s):

Volkmar Mueller ◽

Andrew Wardley ◽

Elisavet Paplomata ◽

Erika Hamilton ◽

Amelia Zelnak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽